18 results about "Diamidopyridine" patented technology

The invention provides a method for preparing 2, 6-diamino-3, 5-dinitropyridine, which comprises the following steps: (1) reacting 2, 6-diaminopyridine with an amino protection reagent to obtain an intermediate A; (2) in the presence of a dehydrating agent, carrying out double nitration reaction on the intermediate A and a nitration reagent to generate an intermediate B; (3) 2, 6-diamino-3, 5-dinitropyridine is obtained after the intermediate B is subjected to deprotection, and an amino protection reagent is selected from one or more of acetic anhydride, trifluoroacetic anhydride, di-tert-butyl dicarbonate, benzyl chloroformate and concentrated sulfuric acid; wherein the molar ratio of the amino protection reagent to the 2, 6-diaminopyridine is (2: 1)-(30: 1) by mole; and preferably, the ratio is 2: 1-12: 1.

The invention discloses a preparation method and application of a poly (2, 6-diaminopyridine) nanosheet with directional self-assembly of single micelle and controllable synthesis of mesopores. The preparation method comprises the following steps: respectively taking 2, 6-diaminopyridine, ammonium persulfate, a block copolymer polyethylene oxide-polystyrene copolymer and graphene oxide as raw materials, taking water, ethanol and tetrahydrofuran as self-assembly dispersing agents, and stirring at a constant speed at normal temperature to prepare the poly (2, 6-diaminopyridine) mesoporous nanosheet. The composite material has a nitrogen-doped carbon chain with a high specific surface area and regular mesopores capable of being used for diffusion, and can be used for storing zinc ions in a negative electrode of a zinc ion battery. The preparation method of the material is simple, low in preparation cost, green, environment-friendly and suitable for large-scale production.

The invention relates to the technical field of medicines, in particular to a 2, 4-diaminopyridine compound as well as a preparation method and application thereof. The compound is shown in the following formula, can achieve strong inhibition on ULK1 enzyme activity, has good inhibition activity on ULK1 and ULK2 kinase, and has good treatment activity on at least one kind of cancer.

The present invention discloses a continuous process for amination of aminopyridines. Particularly, the invention provides a two-step or multi-step process comprising a first continuous nitration step followed by a continuous hydrogenation step to introduce an amino group to an 2-aminopyridine in meta position. Such diaminopyridine compounds are valuable starting materials in the manufacture of active pharmaceutical ingredients.

The application discloses a synthesis method of porous silica colloidal spheres, and relates to the technical field of biological medicines. The method comprises the following steps: 2,6-diaminopyridine is dissolved in a mixed solvent and dissolved by stirring; sodium hydroxide aqueous solution and ethylenediamine are added into the mixed solution, and tetraethyl orthosilicate and glyoxal are sequentially added into the mixed solution; the solution is transferred into a centrifugal tube, supernatant is poured away, the solid at the bottom of the centrifugal tube is reserved, and the solid is dispersed again by using ethanol; the obtained solid is dried in an oven, etching is carried out by using hydrofluoric acid, and porous silica colloidal spheres are obtained after centrifugal drying. In the application, a brand-new synthesis idea is designed by copolymerization of 2,6-diaminopyridine, ethylenediamine, glyoxal and tetraethyl orthosilicate, and by coating of an alkaline polymer, controllable etching of silicon is realized, and uniform porous silica colloidal spheres and silica colloidal spheres with a loose porous eggshell structure and a compact solid yolk structure are obtained.

The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.

The invention provides a reactive heterocyclic aromatic polyamide polymer, an aramid fiber, a preparation method and application. The reactive heterocyclic aromatic polyamide polymer is mainly formed by carrying out copolycondensation on p-phenylenediamine, 2, 5-diaminopyridine, terephthaloyl chloride and acyl chloride A containing a halogenated group in a solvent; the preparation method of the polymer comprises the following steps: mixing and dissolving the cosolvent and the solvent; adding p-phenylenediamine and 2, 5-diaminopyridine, and cooling to-20 to 0 DEG C; and adding terephthaloyl chloride and acyl chloride A containing a halogenated group, and neutralizing a byproduct generated by the polymerization reaction by using an acid-binding agent to obtain a reactive heterocyclic aromatic polyamide polymer solution. And preparing the reactive heterocyclic polyamide polymer solution into the reactive heterocyclic aramid fiber through a dry-jet wet spinning process. A heterocyclic ring structure and a halogenated aromatic ring structure are introduced into a main chain of the prepared reactive heterocyclic aramid fiber, so that reaction conditions are provided for subsequent functional modification, and the application field is expanded.

The invention provides a preparation method of a self-repairing polyurethane material based on multiple hydrogen-bond interaction. The preparation method comprises the following steps: firstly, synthesizing acryloyl chloride and glycinamide hydrochloride to obtain acryloyl glycinamide with a bisamide structure; a novel T-shaped chain extender glycyl dihydroxy amine (OH-NAGA-OH) carrying multiple hydrogen bond groups on a side chain is synthesized through the reaction of acryloyl glycyl amide and diethanol amine. The preparation method comprises the following steps: taking polytetrahydrofuran glycol (PTMG) and polydimethylsiloxane (PDMS) as flexible chain segments, taking the flexible chain segments as soft segments of polyurethane, taking isophorone diisocyanate as a hard segment, taking glycyl dihydroxylamine (OH-NAGA-OH) and 2, 6-diaminopyridine (DAP) as chain extenders, and carrying out polymerization reaction according to a molar ratio of PTMG to PDMS to OH-NAGA-OH to DAP of 1: 1: 2: 2, so as to obtain the self-repairing polyurethane material with multiple hydrogen-bond interaction. The polymer has excellent mechanical and self-healing capabilities, and provides more possibilities for application in materials of protective coatings, wearable electronics, flexible electronics, high-end equipment and the like.

The invention is directed to a process to prepare an aluminium salphen complex by reacting (i) a diamine compound selected from the group of an optionally substituted benzene-1,2-diamine, an optionally substituted 2,3-diaminopyridine and an optionally substituted 3,4-diaminopyridine, (ii) an optionally substituted salicylaldehyde or an optionally substituted 2-hydroxy-1-naphthaldehyde and (iii) aluminium diacetate chloride in a liquid reaction mixture also comprising an alcohol and a base compound.

The present invention provides a first-agent hair dye composition that dyes light-colored hair a vivid primary red color, exhibiting high red color saturation and excellent colorfastness. [Solution] A first hair dyeing agent composition containing one or more selected from (A) 1-hydroxyethyl-4,5-diaminopyrazole, (B) 2,6-diaminopyridine, and (C) 5-(2-hydroxyethylamino)-2-methylphenol or m-aminophenol, wherein the mass ratio of component (C) to component (B) [(C) / (B)] is 0.10 to 0.80.

The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.

To provide a method for treating a sexual dysfunction.SOLUTION: The present disclosure relates to a method for treating female or male sexual dysfunction, the method comprising orally administering to a female or male subject an effective amount of 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof. For example, a method for treating sexual dysfunction in a subject in need thereof is provided, the method comprising orally administering to the subject an effective amount of 3,4-diaminopyridine phosphate.SELECTED DRAWING: None

The invention discloses a high-temperature and high-acid stable heavy metal chelating agent as well as a preparation method and application thereof, and belongs to the field of industrial wastewater treatment. The preparation method comprises the following steps: condensing 2, 6-diaminopyridine and o-phenylenediamine which are used as raw materials to obtain 2, 6-bis (benzimidazole-2-yl) pyridine; nitration and reduction are carried out, and amino groups are introduced; carrying out amidation reaction on the amination intermediate and 2-mercaptobenzothiazole-5-carboxylic acid, and introducing a thiol group; and carrying out nucleophilic substitution reaction on the obtained intermediate and bromohexadecane, and grafting a hydrophobic long chain to finally prepare the target chelating agent. Molecules of the chelating agent integrate a rigid heterocyclic ring, a thiol ligand and a hydrophobic chain, so that the chelating agent not only can efficiently and selectively chelate heavy metal ions under the conditions of high temperature and strong acid, but also can spontaneously gather after chelating and quickly settle through gravity to realize efficient solid-liquid separation, and has a wide application prospect.

The invention belongs to the technical field of photocatalysis, and particularly relates to a squaric acid-pyridine diamine polymer and a preparation method and application thereof.The preparation method includes the steps that squaric acid and 2, 6-diaminopyridine are subjected to a solvothermal reaction to form a Schiff base polymer, and the squaric acid-pyridine diamine polymer is obtained. The spectral response range of the D-A polymer is widened, the separation efficiency of electrons and holes is improved, and H2O2 in-situ generation is enhanced. The squaric acid-pyridine diamine polymer prepared by the method disclosed by the invention is used as a catalyst, the light absorption range of the squaric acid-pyridine diamine polymer is widened to the infrared range, and H2O2 can be prepared by utilizing a visible light source and pure water without the existence of a sacrificial agent.

The invention relates to the field of medicinal chemistry, and particularly discloses a novel TLR8 agonist intermediate as well as a preparation method and application thereof, which are suitable for process development of 4, 6-diaminopyridino [3, 2-d] pyrimidine TLR8 agonists. According to the preparation method, tert-butyl is adopted to replace 2, 4-dimethoxybenzyl to serve as an amino protecting group, so that the crystallization property of the intermediate is remarkably improved, column chromatography is avoided, the cost is reduced, and the process stability is improved. The preparation method of the TLR8 agonist intermediate comprises the steps of reduction, acylating chlorination, coupling, amination and the like, has the advantages of being easy and convenient to operate, high in yield, environmentally friendly and the like, and is particularly suitable for industrial production.

The application belongs to the field of medicine synthesis, and particularly relates to a preparation method of a URAT1 inhibitor intermediate. The method takes 2,3-diaminopyridine (salt) and 1-bromo-4-bromomethylnaphthalene as raw materials, stirs, monitors by HPLC, filters, paddles, and dries to obtain the product. The application can synthesize the product by only one reaction N 3 -[(4-bromonaphthalen-1-yl)methyl]-2,3-diaminopyridine (salt) is low in cost, simple, efficient, has a product yield of 65%-98%, a purity of 86-98%, and is suitable for industrial large-scale production.

The invention relates to the technical field of fluorescence sensing and food safety detection, in particular to a carbon quantum dot for mercury ion fluorescence detection and a preparation method and application thereof.According to the method, 2, 3-diaminopyridine serves as a C source and an N source, boric acid serves as a boron source, and N and B synergistically doped carbon quantum dots are synthesized in one step through a microwave method; a fluorescence sensing system with specific recognition capability on Hg < 2 + > is constructed, compared with traditional blue light carbon quantum dots, the carbon quantum dot has the emission wavelength of 425-520 nm, belongs to a long wavelength region, has the linear range of 0-25 [mu] mol / L, and can meet the detection requirements of trace-to-trace Hg < 2 + >; the detection limit of mercury ions (Hg < 2 + >) is as low as 32.8 nmol / L, which is far lower than the allowable concentration of Hg < 2 + > in food specified in food safety standards, and the problems of low sensitivity and poor stability of Hg < 2 + > detection based on carbon quantum dots in the prior art are solved.

Provided herein are methods of determining NAT acetylation status of a subject with 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.